

CURRENT PERSPECTIVES IN HAEMATOLOGICAL MALIGNANCIES

Wednesday 4th July 2018

Cavendish Conference Centre, 22 Duchess Mews, London W1G 9DT

Chairs: Dr George Follows (Cambridge) and Professor Graham Jackson (Newcastle)

10.30 *Registration*

11.00 CLL - heading for a cure?
(5 mins Q)

Dr George Follows
Addenbrooke's Hospital, Cambridge

11.35 **DEBATES:**

ECHELON 1 : Brentuximab should be used first line
in advanced Hodgkin lymphoma

Chair: Dr George Follows, Cambridge
For: Professor Tim Illidge, Manchester
Against: Dr Wendy Osborne, Newcastle

GALLIUM : Obinutuzumab, not rituximab, should
be used first line for patients with symptomatic
follicular lymphoma

Chair: Professor Tim Illidge, Manchester
For: Dr Wendy Osborne, Newcastle
Against: Dr Graham Collins, Oxford

12.45 *Lunch*

13.45 Continuous therapy in myeloma - the future
(5 mins Q)

Professor Graham Jackson
NCCC, Newcastle

14.20 The impact of the new licensed therapies in AML
(5 mins Q)

Dr Mike Dennis
Christie Hospital, Manchester

14.55 *Coffee*

15.15 High risk and resistant CML: new diagnostic tools
and treatment approaches (5 mins Q)

Dr Hugues de Lavallade
King's College Hospital, London

15.50 Myeloproliferative neoplasms - current thinking
(5 mins Q)

Professor Claire Harrison
Guy's and St Thomas' Hospital, London

16.25 *Close*

REGISTRATION:

STANDARD (until 19 th June)	LATE (from 20 th June)
Consultants: £72 Trainees/Nurses: £60 20 free places available for Trainees/Nurses	£108

Fees inclusive of VAT at 20%

Online registration now open at www.hartleytaylor.co.uk

To check availability for one of the free places or for any further information, please contact
alex@hartleytaylor.co.uk or telephone 01565 621967

This meeting is kindly sponsored by:



The sponsors have had no influence over the content of the agenda or speaker selection